TriSalus Life Sciences, Inc. (TLSI): Nasdaq/NYSE listing notice — MedTech Acquisition receives Nasdaq deficiency notice for MVLS below $35M minimum

TriSalus Life Sciences, Inc.

Nasdaq notified MTAC on June 14, 2023 of MVLS deficiency below $35M for 30 consecutive business days.
Company has 180 days (until Dec 11, 2023) to regain compliance by closing at $35M+ for 10 consecutive days.
No immediate impact on listing or trading; MTAC will monitor and consider available options.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

TriSalus Life Sciences, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

June 14, 2023, MedTech Acquisition Corporation, a Delaware corporation (the “Company”), received a deficiency letter (the “Notice”) of non-compliance from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the preceding 30 consecutive business days, the Company’s Market Value of Listed Securities (“MVLS”) was below the $35 million minimum requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”). The Notice has no immediate effect on the Company’s Na

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

TriSalus Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-073335

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.